IBZL:LSE:LSE-iShares MSCI Brazil UCITS ETF USD (Dist) GBP (GBX)

ETF | Others |

Last Closing

USD 1803.25

Change

0.00 (0.00)%

Market Cap

N/A

Volume

6.57K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-31 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.14 (+0.12%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.12 (+0.64%)

USD 557.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.01 (+0.09%)

USD 496.18B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.45 (-0.63%)

USD 266.08B
0QZO:LSE 0QZO

+1.60 (+1.80%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.21 (+0.69%)

USD 209.75B
0QZ3:LSE Qualcomm Inc.

+1.37 (+0.83%)

USD 202.26B
0R24:LSE Intel Corp.

+0.42 (+2.15%)

USD 196.14B

ETFs Containing IBZL:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.01% 7% C- 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.01% 7% C- 15% F
Trailing 12 Months  
Capital Gain -9.67% 10% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.67% 10% F 22% F
Trailing 5 Years  
Capital Gain -30.55% 8% B- 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.55% 8% B- 19% F
Average Annual (5 Year Horizon)  
Capital Gain -0.39% N/A N/A 36% F
Dividend Return -0.34% N/A N/A 36% F
Total Return 0.06% N/A N/A 30% F
Risk Return Profile  
Volatility (Standard Deviation) 16.66% N/A N/A 59% D-
Risk Adjusted Return -2.02% N/A N/A 36% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike